Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (1185)	12/21/1997 4:24:00 PM
From: Bill Wexler	Respond to of 7041

LOL!! Yeah.....right!!!! Zonagen is a scam. End of story.

To: Dauntless who wrote (1185)	12/21/1997 6:07:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 7041

To all - this is getting good Now our resident biotech/pharmaceutical genius is making the same claims for TXB. Claims that the situation there is the same as the one he has constructed for Zonagen. Lets look at some facts - not a single rumor in list 1- TXB has completed their clinical trials on their first drug - Argatroban. The submitted indication was as an anticoagulant to replace heparin in patients that have developed Heparin INduced Thrombocytopenia (HIT). 2- TXB has submitted their NDA for Argatroban to the FDA, it has been preliminarily reviewed and accepted AND it has been granted expedited review. A decision is expected from the FDA in Feb. 3- TXB has licensed this compound from a Japanese company. It has been on the market in Japan for use in disolving clots in stroke patients for 3-4 years. 4- TXB has signed a distribution agreement with SmithKline & has received the upfront payment & the milestone payment for filing the NDA. 5- TXB was formed by the transfer of technology from the University of Texas Medical School. The company's Medical Director is Dr. Willerson, one of the leading Cardiovascular specialists in the world. Here is his bio -http://www.uth.tmc.edu/schools/med/imed/chairbio.htm 6- TXB has two other compounds in clinical trials and a FULL pipeline of others in development. That's not everything there is to know about this company, but it is all true. If this is a different picture than the one you heard earlier - well, what can I say. It's incredible the depths to which some folks will go in order to sound like they know something.